Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathway.

Kuo HP, Lee DF, Chen CT, Liu M, Chou CK, Lee HJ, Du Y, Xie X, Wei Y, Xia W, Weihua Z, Yang JY, Yen CJ, Huang TH, Tan M, Xing G, Zhao Y, Lin CH, Tsai SF, Fidler IJ, Hung MC.

Sci Signal. 2010 Feb 9;3(108):ra9. doi: 10.1126/scisignal.2000590.

2.

Up-regulation of human arrest-defective 1 protein is correlated with metastatic phenotype and poor prognosis in breast cancer.

Wang ZH, Gong JL, Yu M, Yang H, Lai JH, Ma MX, Wu H, Li L, Tan DY.

Asian Pac J Cancer Prev. 2011;12(8):1973-7.

3.

Phosphorylation of ARD1 by IKKbeta contributes to its destabilization and degradation.

Kuo HP, Lee DF, Xia W, Lai CC, Li LY, Hung MC.

Biochem Biophys Res Commun. 2009 Nov 6;389(1):156-61. doi: 10.1016/j.bbrc.2009.08.127. Epub 2009 Aug 28.

4.

AKT3 promotes prostate cancer proliferation cells through regulation of Akt, B-Raf, and TSC1/TSC2.

Lin HP, Lin CY, Huo C, Jan YJ, Tseng JC, Jiang SS, Kuo YY, Chen SC, Wang CT, Chan TM, Liou JY, Wang J, Chang WS, Chang CH, Kung HJ, Chuu CP.

Oncotarget. 2015 Sep 29;6(29):27097-112. doi: 10.18632/oncotarget.4553.

5.

Critical role of arachidonic acid-activated mTOR signaling in breast carcinogenesis and angiogenesis.

Wen ZH, Su YC, Lai PL, Zhang Y, Xu YF, Zhao A, Yao GY, Jia CH, Lin J, Xu S, Wang L, Wang XK, Liu AL, Jiang Y, Dai YF, Bai XC.

Oncogene. 2013 Jan 10;32(2):160-70. doi: 10.1038/onc.2012.47. Epub 2012 Feb 20.

PMID:
22349822
6.

Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.

Jaeschke A, Hartkamp J, Saitoh M, Roworth W, Nobukuni T, Hodges A, Sampson J, Thomas G, Lamb R.

J Cell Biol. 2002 Oct 28;159(2):217-24. Epub 2002 Oct 28.

7.

Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma.

Chakraborty S, Mohiyuddin SM, Gopinath KS, Kumar A.

BMC Cancer. 2008 Jun 6;8:163. doi: 10.1186/1471-2407-8-163.

8.

Tuberous-sclerosis complex-related cell signaling in the pathogenesis of lung cancer.

Fuchs A, König K, Heukamp LC, Fassunke J, Kirfel J, Huss S, Becker AJ, Büttner R, Majores M.

Diagn Pathol. 2014 Mar 4;9:48. doi: 10.1186/1746-1596-9-48.

9.

REDD2 is enriched in skeletal muscle and inhibits mTOR signaling in response to leucine and stretch.

Miyazaki M, Esser KA.

Am J Physiol Cell Physiol. 2009 Mar;296(3):C583-92. doi: 10.1152/ajpcell.00464.2008. Epub 2009 Jan 7.

10.

Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation.

Goncharova EA, Goncharov DA, Chisolm A, Spaits MS, Lim PN, Cesarone G, Khavin I, Tliba O, Amrani Y, Panettieri RA Jr, Krymskaya VP.

Mol Pharmacol. 2008 Mar;73(3):778-88. Epub 2007 Dec 19.

11.

Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR.

Dere R, Wilson PD, Sandford RN, Walker CL.

PLoS One. 2010 Feb 16;5(2):e9239. doi: 10.1371/journal.pone.0009239.

12.

Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.

Kwiatkowski DJ, Manning BD.

Hum Mol Genet. 2005 Oct 15;14 Spec No. 2:R251-8. Review.

PMID:
16244323
13.

Insulin like growth factor-1-induced phosphorylation and altered distribution of tuberous sclerosis complex (TSC)1/TSC2 in C2C12 myotubes.

Miyazaki M, McCarthy JJ, Esser KA.

FEBS J. 2010 May;277(9):2180-91. doi: 10.1111/j.1742-4658.2010.07635.x.

14.

Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.

Mi R, Ma J, Zhang D, Li L, Zhang H.

J Genet Genomics. 2009 Jun;36(6):355-61. doi: 10.1016/S1673-8527(08)60124-1.

PMID:
19539245
15.
16.

Analysis of gene expression array in TSC2-deficient AML cells reveals IRF7 as a pivotal factor in the Rheb/mTOR pathway.

Makovski V, Jacob-Hirsch J, Gefen-Dor C, Shai B, Ehrlich M, Rechavi G, Kloog Y.

Cell Death Dis. 2014 Dec 4;5:e1557. doi: 10.1038/cddis.2014.502.

17.

Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.

Huang J, Wu S, Wu CL, Manning BD.

Cancer Res. 2009 Aug 1;69(15):6107-14. doi: 10.1158/0008-5472.CAN-09-0975. Epub 2009 Jul 14.

18.

Acetylation of androgen receptor by ARD1 promotes dissociation from HSP90 complex and prostate tumorigenesis.

DePaolo JS, Wang Z, Guo J, Zhang G, Qian C, Zhang H, Zabaleta J, Liu W.

Oncotarget. 2016 Nov 1;7(44):71417-71428. doi: 10.18632/oncotarget.12163.

19.

mTOR Hyperactivation by Ablation of Tuberous Sclerosis Complex 2 in the Mouse Heart Induces Cardiac Dysfunction with the Increased Number of Small Mitochondria Mediated through the Down-Regulation of Autophagy.

Taneike M, Nishida K, Omiya S, Zarrinpashneh E, Misaka T, Kitazume-Taneike R, Austin R, Takaoka M, Yamaguchi O, Gambello MJ, Shah AM, Otsu K.

PLoS One. 2016 Mar 29;11(3):e0152628. doi: 10.1371/journal.pone.0152628. eCollection 2016.

20.

Tuberous sclerosis complex: linking cancer to metabolism.

Mieulet V, Lamb RF.

Trends Mol Med. 2010 Jul;16(7):329-35. doi: 10.1016/j.molmed.2010.05.001. Epub 2010 Jun 3. Review.

PMID:
20605525

Supplemental Content

Support Center